{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T01:06:06Z","timestamp":1781831166407,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jpba.2020.113132","type":"journal-article","created":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T11:32:59Z","timestamp":1579951979000},"page":"113132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["A new validated HPLC-UV method for therapeutic monitoring of daptomycin in comparison with reference mass spectrometry"],"prefix":"10.1016","volume":"182","author":[{"given":"Giacomo","family":"Luci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Cucchiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ciofi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Lastella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2020.113132_bib0005","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/dkh546","article-title":"Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections","volume":"55","author":"Steenbergen","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2020.113132_bib0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1469-0691.2005.01138.x","article-title":"Current and emerging serious Gram-positive infections","volume":"11","author":"Menichetti","year":"2005","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.jpba.2020.113132_bib0015","article-title":"The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections","volume":"12","author":"Arbeit","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jpba.2020.113132_bib0020","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1128\/AAC.01608-12","article-title":"Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis","volume":"57","author":"Tascini","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2020.113132_bib0025","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1128\/AAC.01774-10","article-title":"Case report of a successful treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) bacteremia and MRSA\/vancomycin-resistant Enterococcus faecium cholecystitis by daptomycin","volume":"55","author":"Tascini","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2020.113132_bib0030","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ijantimicag.2008.12.007","article-title":"Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin\u00ae Outcomes Registry and Experience (CORE)","volume":"33","author":"Mohr","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jpba.2020.113132_bib0035","first-page":"563","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","author":"Fowler","year":"2008","journal-title":"LibNew Engl. Journalrary"},{"key":"10.1016\/j.jpba.2020.113132_bib0040","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2020.113132_bib0045","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","article-title":"Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers","volume":"50","author":"Benvenuto","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2020.113132_bib0050","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijantimicag.2013.06.006","article-title":"Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections","volume":"42","author":"Di Paolo","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jpba.2020.113132_bib0055","first-page":"318","article-title":"Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers","volume":"36","author":"Nyhart","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2020.113132_bib0060","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/jac\/dki476","article-title":"Rhabdomyolysis and acute renal failure in a patient treated with daptomycin","volume":"57","author":"Kazory","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2020.113132_bib0065","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jac\/dki058","article-title":"Severe myopathy and possible hepatotoxicity related to daptomycin","volume":"55","author":"Echevarria","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2020.113132_bib0070","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jac\/dkp127","article-title":"Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor","volume":"63","author":"Odero","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2020.113132_bib0075","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1093\/cid\/ciu230","article-title":"Different recommendations for daptomycin dosing over time in patients with severe infections","volume":"58","author":"Di Paolo","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jpba.2020.113132_bib0080","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10156-013-0559-z","article-title":"Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?","volume":"19","author":"Falcone","year":"2013","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.jpba.2020.113132_bib0085","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1515\/cclm-2019-0429","article-title":"Appropriateness of repetitive therapeutic drug monitoring and laboratory turnaround time","volume":"57","author":"Sarli","year":"2019","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.jpba.2020.113132_bib0090","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jevs.2015.08.012","article-title":"Withdrawal time of phenylbutazone administered to healthy horses","volume":"35","author":"Meucci","year":"2015","journal-title":"J. Equine Vet. Sci."},{"key":"10.1016\/j.jpba.2020.113132_bib0095","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.mex.2016.03.006","article-title":"Determination of ochratoxin A in pig tissues using enzymatic digestion coupled with high-performance liquid chromatography with a fluorescence detector","volume":"3","author":"Luci","year":"2016","journal-title":"MethodsX"},{"key":"10.1016\/j.jpba.2020.113132_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12550-017-0292-z","article-title":"Determination of ochratoxin A in tissues of wild boar (Sus scrofa L.) by enzymatic digestion (ED) coupled to high-performance liquid chromatography with a fluorescence detector (HPLC-FLD)","volume":"34","author":"Luci","year":"2017","journal-title":"Mycotoxin Res."},{"key":"10.1016\/j.jpba.2020.113132_bib0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1515\/CCLM.2011.005","article-title":"Determination of daptomycin in human plasma by liquid chromatography-tandem mass spectrometry. Clinical application","volume":"49","author":"Verdier","year":"2011","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.jpba.2020.113132_bib0110","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jpba.2013.08.022","article-title":"Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots","volume":"88","author":"Baietto","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2020.113132_bib0115","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jchromb.2008.09.019","article-title":"Validated high performance liquid chromatography-UV detection method for the determination of daptomycin in human plasma","volume":"875","author":"Martens-Lobenhoffer","year":"2008","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2020.113132_bib0120","series-title":"Bioanalytical Method Validation Guidance for Industry","first-page":"1","author":"Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.jpba.2020.113132_bib0125","series-title":"Antibiotics in Plasma by LC-MS\/MS 500 Test New","author":"Eureka","year":"2020"},{"key":"10.1016\/j.jpba.2020.113132_bib0130","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/cid\/cit582","article-title":"Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant staphylococcus aureus bacteremia","volume":"57","author":"Falcone","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jpba.2020.113132_bib0135","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijantimicag.2013.06.006","article-title":"Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections","volume":"42","author":"Di Paolo","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jpba.2020.113132_bib0140","series-title":"Clinical Breakpoints and Dosing of Antibiotics","author":"EUCAST","year":"2019"},{"key":"10.1016\/j.jpba.2020.113132_bib0145","first-page":"32","article-title":"Mechanisms of drug resistance: daptomycin resistance","volume":"39","author":"Tran","year":"2015","journal-title":"HHS Public Access."},{"key":"10.1016\/j.jpba.2020.113132_bib0150","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin. Infect. Dis."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519327682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519327682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:59:32Z","timestamp":1760000372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708519327682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":30,"alternative-id":["S0731708519327682"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113132","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new validated HPLC-UV method for therapeutic monitoring of daptomycin in comparison with reference mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113132"}}